Imaging Studies and the Development of Multiple Myeloma

Summary

Background: \- Multiple myeloma (MM) is a type of malignant blood cancer. It affects the plasma cells, which help produce antibodies and fight infection. MM is nearly always preceded by a pre-malignant state, monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). Currently, it is not possible to predict when someone with MGUS or SMM will develop MM. Also, the disease changes in those early states are not well understood. Researchers want to look at imaging studies of people with MGUS, SMM, and MM. They will study whether the growth of blood vessels can be used to predict disease progression. Objectives: \- To use imaging studies to evaluate disease progression in multiple myeloma. Eligibility: \- Individuals at least 18 years of age who have MGUS, SMM, or newly diagnosed MM. Design: * Participants will be screened with a physical exam and medical history. They will also have blood and urine tests, and provide bone marrow samples. * Participants will have positron emission tomography (PET) scans with the new contrast agent \[18\]F-Fluciclatide. The contrast agent is intended to show patterns of increased vessel growth in the bone marrow. * Participants will also have a magnetic resonance imaging (MRI) scan. This scan will be done according to standard procedures. * Researchers will compare these scans with blood tests and other clinical information to study disease progression of MGUS, SMM, and MM.

Timeline

Start

2012-03-27

Primary completion

2014-04-23

Completion

2014-04-23

Publications

• Background Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008 Mar 15;111(6):2962-72. doi: 10.1182/blood-2007-10-078022.
• Background International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003 Jun;121(5):749-57.
• Background Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008 Mar 1;111(5):2516-20. doi: 10.1182/blood-2007-10-116129. Epub 2007 Nov 1.

Drugs

Indications